	US 11,678,685 B2
	Glucosyl stevia composition
Avetik Markosyan, Yerevan (AM)
Assigned to PureCircle Sdn Bhd, Kuala Lumpur (MY)
Filed by PureCircle Sdn Bhd, Kuala Lumpur (MY)
Filed on Oct. 24, 2016, as Appl. No. 15/332,760.
Application 15/332,760 is a division of application No. 14/352,832, granted, now 9,474,296, previously published as PCT/US2012/052659, filed on Aug. 28, 2012.
Application 13/567,707 is a division of application No. 13/029,263, filed on Feb. 17, 2011, granted, now 8,257,948, issued on Sep. 4, 2012.
Application 13/567,707 is a continuation in part of application No. 13/567,707, filed on Aug. 6, 2012, granted, now 8,647,844, issued on Feb. 11, 2014.
Claims priority of provisional application 61/580,274, filed on Dec. 26, 2011.
Claims priority of provisional application 61/548,818, filed on Oct. 19, 2011.
Prior Publication US 2017/0035086 A1, Feb. 9, 2017
Int. Cl. A23L 27/30 (2016.01); A23C 9/13 (2006.01); A23L 2/60 (2006.01); A21D 2/36 (2006.01); A61K 36/28 (2006.01); C12P 19/18 (2006.01); C12P 19/56 (2006.01); C12P 33/00 (2006.01); A21D 2/18 (2006.01); A21D 13/062 (2017.01); A61K 31/704 (2006.01); A23L 29/30 (2016.01); A23L 33/21 (2016.01); A23L 27/00 (2016.01); A23L 2/02 (2006.01)

CPC A23L 27/33 (2016.08) [A21D 2/181 (2013.01); A21D 2/36 (2013.01); A21D 13/062 (2013.01); A23C 9/1307 (2013.01); A23L 2/02 (2013.01); A23L 2/60 (2013.01); A23L 27/00 (2016.08); A23L 27/30 (2016.08); A23L 27/31 (2016.08); A23L 27/32 (2016.08); A23L 27/34 (2016.08); A23L 27/35 (2016.08); A23L 27/36 (2016.08); A23L 29/35 (2016.08); A23L 29/37 (2016.08); A23L 33/21 (2016.08); A61K 31/704 (2013.01); A61K 36/28 (2013.01); C12P 19/18 (2013.01); C12P 19/56 (2013.01); C12P 33/00 (2013.01); A23V 2002/00 (2013.01)]

5 Claims

1. A food, beverage, cosmetic or pharmaceutical product comprising a highly purified glucosyl rebaudioside B composition made by a process comprising the steps of:

adding starch into water to form a starch suspension;

adding a mixture of α-amylase and CGTase into the starch suspension and incubating for about 0.5 to 2 hours at about 75-80° C., resulting in a liquefied starch suspension;

inactivating the α-amylase by low pH heat treatment;

cooling the liquefied starch suspension and adjusting the pH to about 5.5 to 7.0;

preparing a freely soluble form of rebaudioside B made by a process comprising the steps of suspending a steviol glycoside composition comprising 95% or more rebaudioside B in 1 to 3 volumes of water to form a suspension, heating the suspension to a temperature of 50-100° C., increasing a pH of the suspension to about 6.0 to 9.0 until the rebaudioside B is completely dissolved to form a solution, and optionally spray-drying the solution,

adding the freely soluble form of rebaudioside B into the liquefied starch suspension, resulting in a reaction mixture;

adding a second batch of CGTase into the reaction mixture and incubating for about 12 to 48 hours at about 55-75° C.; inactivating the CGTase by low heat treatment;

decolorizing the reaction mixture;

cooling the reaction mixture and adjusting the pH to about 2.0 to 4.5;

precipitating a portion of unreacted Rebaudioside B;

separating the precipitated unreacted Rebaudioside B crystals from filtrate;

adjusting the pH of filtrate to about 5.5 to 7.0;

removing impurities by contacting the filtrate with macroporous adsorbent resin and subsequently eluting adsorbed diterpene glycosides with aqueous ethanol to result in a glycoside-containing aqueous ethanol eluate;

removing ethanol from the aqueous ethanol eluate, resulting in an aqueous eluate; and

concentrating and drying the aqueous eluate to obtain the highly purified glucosyl rebaudioside B composition,

wherein the highly purified glucosyl rebaudioside B composition comprises a mixture of derivatives containing more than one α-1,4-glucosyl residues attached to glycosidic residues of C13 position of rebaudioside B, and unmodified steviol glycosides,

wherein the highly purified glucosyl rebaudioside B composition contains mainly rebaudioside B α-1,4-glucosyl derivatives, and

wherein the precipitating and separating steps increase the ratio of rebaudioside B α-1,4,-derivatives to unreacted rebaudioside B in the reaction mixture.